Kyntra Bio Statistics
Total Valuation
Kyntra Bio has a market cap or net worth of $27.12 million. The enterprise value is -$40.87 million.
| Market Cap | 27.12M |
| Enterprise Value | -40.87M |
Important Dates
The next confirmed earnings date is Monday, August 3, 2026, after market close.
| Earnings Date | Aug 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kyntra Bio has 4.05 million shares outstanding. The number of shares has increased by 0.59% in one year.
| Current Share Class | 4.05M |
| Shares Outstanding | 4.05M |
| Shares Change (YoY) | +0.59% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 2.15% |
| Owned by Institutions (%) | 14.61% |
| Float | 3.56M |
Valuation Ratios
The trailing PE ratio is 0.17.
| PE Ratio | 0.17 |
| Forward PE | n/a |
| PS Ratio | 3.65 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.61
| Current Ratio | 3.61 |
| Quick Ratio | 3.42 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.97 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -20.17% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -54.40% |
| Weighted Average Cost of Capital (WACC) | 20.88% |
| Revenue Per Employee | $218,794 |
| Profits Per Employee | $4.81M |
| Employee Count | 34 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 8.05 |
Taxes
| Income Tax | -92,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.97% in the last 52 weeks. The beta is 0.99, so Kyntra Bio's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | +14.97% |
| 50-Day Moving Average | 6.99 |
| 200-Day Moving Average | 8.62 |
| Relative Strength Index (RSI) | 43.51 |
| Average Volume (20 Days) | 31,785 |
Short Selling Information
The latest short interest is 116,425, so 2.88% of the outstanding shares have been sold short.
| Short Interest | 116,425 |
| Short Previous Month | 113,844 |
| Short % of Shares Out | 2.88% |
| Short % of Float | 3.27% |
| Short Ratio (days to cover) | 14.25 |
Income Statement
In the last 12 months, Kyntra Bio had revenue of $7.44 million and earned $163.62 million in profits. Earnings per share was $40.45.
| Revenue | 7.44M |
| Gross Profit | -18.88M |
| Operating Income | -44.34M |
| Pretax Income | -56.66M |
| Net Income | 163.62M |
| EBITDA | -43.92M |
| EBIT | -44.34M |
| Earnings Per Share (EPS) | $40.45 |
Balance Sheet
The company has $87.24 million in cash and $19.25 million in debt, with a net cash position of $67.99 million or $16.79 per share.
| Cash & Cash Equivalents | 87.24M |
| Total Debt | 19.25M |
| Net Cash | 67.99M |
| Net Cash Per Share | $16.79 |
| Equity (Book Value) | -9.29M |
| Book Value Per Share | -10.82 |
| Working Capital | 73.24M |
Cash Flow
In the last 12 months, operating cash flow was -$21.38 million and capital expenditures -$22,000, giving a free cash flow of -$21.40 million.
| Operating Cash Flow | -21.38M |
| Capital Expenditures | -22,000 |
| Depreciation & Amortization | 428,000 |
| Net Borrowing | -80.56M |
| Free Cash Flow | -21.40M |
| FCF Per Share | -$5.29 |
Margins
Gross margin is -253.78%, with operating and profit margins of -596.10% and 2,199.42%.
| Gross Margin | -253.78% |
| Operating Margin | -596.10% |
| Pretax Margin | -761.69% |
| Profit Margin | 2,199.42% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kyntra Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.59% |
| Shareholder Yield | -0.59% |
| Earnings Yield | 603.25% |
| FCF Yield | -78.91% |
Analyst Forecast
The average price target for Kyntra Bio is $43.00, which is 536.10% higher than the current price. The consensus rating is "Buy".
| Price Target | $43.00 |
| Price Target Difference | 536.10% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 1.33% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 17, 2025. It was a reverse split with a ratio of 1:25.
| Last Split Date | Jun 17, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
Kyntra Bio has an Altman Z-Score of -22.27 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -22.27 |
| Piotroski F-Score | 5 |